# Pasithea Therapeutics Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Pasithea Therapeutics Corp.). ## Overview Pasithea Therapeutics Corp. is a U.S.-based biotechnology company focused on discovering and developing therapies for central nervous system and other serious diseases. Its portfolio includes clinical-stage and discovery-stage programs, with operations conducted through a group of U.S., Australian, Portuguese, and former U.K. subsidiaries. ## Products & services • PAS-004 clinical-stage therapeutic program • PAS-003 discovery-stage ALS program • PAS-001 discovery-stage schizophrenia program • Drug discovery and preclinical development • Clinical development and regulatory advancement - **Clinical-stage drug programs** (0%) — Therapeutic candidates being advanced through clinical development and regulatory review. - **Discovery-stage programs** (0%) — Early-stage research programs aimed at identifying new drug candidates for CNS diseases. - **Preclinical research and development** (0%) — Laboratory and translational work supporting target validation and candidate selection. - **Corporate and development operations** (100%) — Internal functions supporting financing, IP, and advancement of the pipeline. - PAS-004 clinical-stage therapeutic program - PAS-003 discovery-stage ALS program - PAS-001 discovery-stage schizophrenia program - Drug discovery and preclinical development - Clinical development and regulatory advancement ## Customers Pasithea does not appear to sell commercial products yet; its primary stakeholders are regulators, clinical investigators, and future healthcare customers that would use approved therapies. The eventual end customers would be patients and physicians in neurology and psychiatry, while near-term counterparties include research partners, capital providers, and clinical service providers supporting development. - **ALS patients and treating clinicians** (emerging) — Future users of PAS-003 if development succeeds; the program targets unmet need in amyotrophic lateral sclerosis. - **Schizophrenia patients and psychiatrists** (emerging) — Future users of PAS-001 if it advances successfully; the program is aimed at a major CNS indication. - **Clinical research ecosystem** (primary) — Trial sites, investigators, CROs, and regulators that support preclinical and clinical advancement. - **Capital providers and strategic partners** (primary) — Equity, debt, and collaboration counterparties that fund development and extend operating runway. - Patients with ALS targeted by PAS-003 - Patients with schizophrenia targeted by PAS-001 - Physicians and hospitals that would prescribe approved therapies - Regulators and trial sites that enable clinical development - Potential collaborators and capital providers funding R&D ## Geography Pasithea is headquartered in the United States and operates through subsidiaries in the U.S. and Australia, with former entities in the U.K. and Portugal now discontinued. Its business is geographically shaped by where research, clinical development, and corporate financing activities can be conducted rather than by commercial sales markets. - Headquartered in the United States - Subsidiaries include Delaware entities and an Australian company - Former U.K. and Portugal operations have been discontinued - Geography matters mainly for R&D execution and corporate structure - No disclosed country revenue mix because the company is pre-commercial ## Strategy Pasithea’s strategy is to advance its pipeline through discovery, preclinical work, and clinical development while preserving access to external capital. The company also emphasizes maintaining intellectual property, building development capabilities, and preparing for eventual commercialization if any candidate is approved. - **Advance lead and discovery programs** (short-term) — Pipeline progression is the main value driver for a pre-commercial biotech. - **Raise external capital** (short-term) — Development programs require funding before any product revenue exists. - **Protect and expand intellectual property** (medium-term) — IP underpins exclusivity and future partnering or commercialization value. - Advance PAS-004 through clinical development - Progress PAS-003 and PAS-001 from discovery into development - Secure additional equity or debt funding to support operations - Build IP and development capabilities around the pipeline - Prepare commercialization infrastructure if a product is approved ## Risks Pasithea faces the typical risks of a pre-revenue biotech: clinical failure, regulatory delay, and the possibility that additional financing is unavailable or dilutive. It also has company-specific listing and capital-market risks, including Nasdaq bid-price compliance and restrictions tied to its public float. - **Pipeline development failure** [critical] — Drug candidates may not show sufficient safety or efficacy in preclinical or clinical testing. - **Financing shortfall** [critical] — The company expects to need additional capital before it can fund development and operations. - **Nasdaq listing compliance** [high] — Failure to maintain bid-price and other listing requirements could trigger delisting. - **Competitive therapeutic landscape** [medium] — Other approved or emerging therapies could limit market opportunity for its candidates. - No commercial revenue yet; success depends on pipeline outcomes - Clinical trials may fail, delay, or produce inconclusive data - Additional capital may be unavailable or highly dilutive - Nasdaq bid-price compliance and possible delisting risk - Competing therapies could reduce the value of its programs ## Accounting As a development-stage biotech, Pasithea’s reported results are driven mainly by R&D expense, stock-based compensation, and fair value measurements rather than product revenue. Investors should also watch going-concern and liquidity-related disclosures, since the company’s ability to continue operations depends on future financing and the timing of clinical progress. - **Research and development expense** — Affects operating loss and cash burn - **Stock-based compensation** — Can materially increase reported expenses - **Fair value measurements** — Affects net income volatility - **Going-concern assessment** — Important for solvency and disclosure analysis - R&D expense reflects clinical and preclinical program spending - Stock-based compensation can materially affect operating losses - Fair value measurements affect warrant and other valuation items - Revenue recognition is not yet a major driver without product sales - Going-concern and liquidity disclosures are important for analysis --- *Last updated: 2026-04-29T04:47:47.440378+00:00*